Loading...
XHKG
6896
Market cap307mUSD
Dec 05, Last price  
3.24HKD
1D
-0.31%
1Q
-7.16%
Jan 2017
8.00%
IPO
-30.62%
Name

Golden Throat Holdings Group Co Ltd

Chart & Performance

D1W1MN
XHKG:6896 chart
P/E
6.83
P/S
1.84
EPS
0.43
Div Yield, %
18.52%
Shrs. gr., 5y
Rev. gr., 5y
8.25%
Revenues
1.19b
+23.26%
548,857,000606,801,000706,922,000768,171,000624,084,000694,194,000797,129,000646,941,000820,543,000992,014,000961,377,0001,185,004,000
Net income
319m
+27.37%
69,918,000121,893,000154,618,000102,912,00061,380,000102,186,000167,613,000154,052,000187,643,000281,218,000250,162,000318,631,000
CFO
476m
+99.25%
180,860,000173,256,00051,235,00013,259,00079,902,000189,208,000215,590,000167,746,000164,889,000271,146,000238,838,000475,874,000
Dividend
Jun 14, 20240.6 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Golden Throat Holdings Group Company Limited, an investment holding company, manufactures and sells pharmaceutical, healthcare food, and other products in the People's Republic of China. It offers Golden Throat lozenges over-the-counter medicine to relive symptoms of sore and dry throat, and hoarse voice caused by acute pharyngitis. It also provides Golden Throat lozenge series products that include Dule lozenges and sugar-free Dule lozenges in various flavors, such as orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn; Yinxingye tablet, which is designed to facilitate blood circulation, remove blood stasis, and dredge energy channels; and herbal vegetable beverages for soothing voice and relieving sore throats. The company also exports its products to the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and Africa. Golden Throat Holdings Group Company Limited was founded in 1956 and is headquartered in Liuzhou, the People's Republic of China.
IPO date
Jul 15, 2015
Employees
860
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT